In liver cancer cells, sorafenib down-regulates the expression of HIF-1α, but up-regulates the expression of HIF-2α, with a final effect of changing the hypoxic response from the HIF-1α-dependent to the HIF-2α-dependent pathway. Here, EPAS1 is linked to liver cancer.